Today: 19 May 2026
Browse Category

NASDAQ:ILMN 22 June 2025 - 5 May 2026

GeneDx Stock Crash: WGS Plunges After Guidance Cut Raises Reimbursement Fears

GeneDx Stock Crash: WGS Plunges After Guidance Cut Raises Reimbursement Fears

GeneDx shares dropped 51% to $33.12 after the company cut its 2026 revenue forecast and lowered full-year guidance to $475–$490 million. First-quarter revenue rose 17% to $102.3 million, but missed expectations as reimbursement rates and product mix hurt sales. The company posted an adjusted net loss of $8.2 million. Management maintained its target for positive adjusted net income this year.
5 May 2026
····
Illumina (ILMN) stock slides 10% after 2026 outlook puts China, research demand back in focus

Illumina (ILMN) stock slides 10% after 2026 outlook puts China, research demand back in focus

Illumina shares dropped 10.3% to $119.91 after the company forecast 2026 revenue of $4.5–$4.6 billion and non-GAAP EPS of $5.05–$5.20. Management cited progress in China but said approvals are still needed for instrument sales. Fourth-quarter revenue rose 5% to $1.16 billion, with ex-China revenue up 8%. The company expects 2026 organic revenue growth of 2–4% excluding China.
6 February 2026
···
Biotech Breakthrough: GRAIL (GRAL) Stock Surges on New Cancer-Detection Data

Biotech Breakthrough: GRAIL (GRAL) Stock Surges on New Cancer-Detection Data

GRAL shares surged to $69.14 intraday on Oct 3, up nearly 6.8% and about 248% year-to-date. Market cap reached $2.3–2.5 billion, a 472% jump since mid-2024, despite ongoing losses and negative EPS. Wall Street consensus remains “Hold” with a $31.50 average price target, far below current levels. Investors await new PATHFINDER 2 trial data at ESMO Congress later this month.
3 October 2025
···
Top 100 Global Biotechnology Companies Revolutionizing Science and Health

Top 100 Global Biotechnology Companies Revolutionizing Science and Health

Pfizer and BioNTech co-developed Comirnaty, the first FDA-approved mRNA COVID-19 vaccine. Roche leads in oncology and diagnostics, while Moderna advanced mRNA vaccines for COVID-19 and other diseases. Illumina dominates DNA sequencing, and CRISPR Therapeutics develops gene-editing therapies for sickle cell disease.
22 June 2025
···········

Stock Market Today

  • South Korea Boosts iShares Emerging Market ETF's Edge
    May 19, 2026, 3:57 PM EDT. The iShares emerging market exchange-traded fund (ETF) holds a competitive edge over its rivals, largely due to heavy exposure to South Korean tech giants Samsung Electronics and SK Hynix. These companies' strong performance in semiconductors and technology sectors is bolstering the ETF's returns. South Korea's market influence is a key differentiator among emerging market ETFs, giving investors access to dynamic growth drivers. This advantage highlights the importance of country-specific weights in shaping fund performance within the volatile emerging markets landscape.

Latest articles

Intel Stock Bounces as Wall Street Rethinks AI Narrative

Intel Stock Bounces as Wall Street Rethinks AI Narrative

19 May 2026
Intel shares climbed 3.3% to $111.69 Tuesday afternoon, rebounding after five sessions of losses as Citi and Benchmark raised price targets, citing stronger CPU demand. Trading volume topped 112 million shares. The move came ahead of Nvidia’s earnings, which options traders expect to trigger a major market shift. Intel CEO Lip-Bu Tan was set to speak at a J.P. Morgan conference later in the day.
Pinterest shares erase post-earnings gains

Pinterest shares erase post-earnings gains

19 May 2026
Pinterest shares fell about 6% Tuesday, trading at $18.74 by 3:05 p.m. EDT, erasing gains from its May earnings rally. The drop outpaced declines in Meta, Snap, and Reddit as the Nasdaq and S&P 500 also slipped. Pinterest reported Q1 revenue of $1.008 billion, up 18%, with a net loss of $74 million. The company forecast Q2 revenue above analyst expectations.
Blue Bird Drops 10% on Pension Charge Update

Blue Bird Drops 10% on Pension Charge Update

19 May 2026
Blue Bird shares dropped 9.6% to $65.75 Tuesday after a new SEC filing revealed an expected material non-cash pension settlement charge for the fiscal third quarter. The company will transfer about $94 million in pension liabilities to Pacific Life via group annuity contracts, affecting 2,044 participants. The move follows recent guidance increases and analyst upgrades. Blue Bird said the transactions will be funded entirely by plan assets.
Go toTop